Maternal recognition of pregnancy.
Enhanced secretion of PGF2 alpha from endometrial explants in vitro in response to oxytocin is associated with augmented activities of phospholipase A2, phospholipase C and prostaglandin endoperoxide H synthase (PGS). In early pregnancy, maintenance of the corpus luteum is associated with an absence of pulsatile PGF2 alpha secretion; an increase in endometrial inhibitors of phospholipase A2 and PGS contribute to the antiluteolytic alterations of PGF2 alpha secretion. Linoleic acid is a competitive inhibitor of arachidonic acid metabolism by PGS, and microsomal concentrations of free linoleic acid are increased in the endometrium of pregnant cattle. The trophoblast produces large quantities of interferon tau (IFN-tau). Inhibition of increases in endometrial oestradiol receptor mRNA and protein are associated with intrauterine administration of recombinant (r) ovine (o) IFN-tau in sheep. Intrauterine injections of ovine (b) IFN-tau in cattle (days 14-17) altered endometrial function so that secretion of PGF2 alpha from cultured endometrial epithelial cells was reduced. Antiluteolytic effects were not expressed in 20% of cows receiving IFN-tau or rbIFN-alpha I1 indicating that an inadequate endometrial responsiveness may contribute to embryo mortality. IFN-tau may activate a signal transduction system similar to that induced by other type I IFNs; activation of an intracellular tyrosine kinase ultimately leads to activation of an IFN-stimulated response element to induce gene transcription. Biological responses associated with pregnancy and IFN-tau treatment are integrated into a multifactorial antiluteolytic model. Strategies to enhance embryo survival could include supplementation with rIFN-tau and alterations in endometrial responsiveness to this cytokine through dietary manipulation of lipid metabolism.
Thatcher
W W
WW
Department of Dairy and Poultry Sciences, University of Florida, Gainesville 32611, USA.
Meyer
M D
MD
Danet-Desnoyers
G
G
D000818:Animals; D002417:Cattle / Q000502:physiology*; D003340:Corpus Luteum Maintenance / Q000502:physiology*; D015237:Dinoprost / Q000378:metabolism; D005260:Female; D005328:Fetal Viability; D007370:Interferon Type I / Q000502:physiology; D008186:Luteolytic Agents / Q000037:antagonists & inhibitors; D011247:Pregnancy; D011257:Pregnancy Proteins / Q000502:physiology; D011270:Pregnancy, Animal / Q000502:physiology*; D012756:Sheep / Q000502:physiology*; D014327:Trophoblasts / Q000502:physiology
D007370:Interferon Type I; D008186:Luteolytic Agents; D011257:Pregnancy Proteins; C020947:interferon tau; D015237:Dinoprost